These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21486874)

  • 1. Policy framework for rare disease health disparities.
    Holtzclaw Williams P
    Policy Polit Nurs Pract; 2011 May; 12(2):114-8. PubMed ID: 21486874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The need for worldwide policy and action plans for rare diseases.
    Forman J; Taruscio D; Llera VA; Barrera LA; Coté TR; Edfjäll C; Gavhed D; Haffner ME; Nishimura Y; Posada M; Tambuyzer E; Groft SC; Henter JI;
    Acta Paediatr; 2012 Aug; 101(8):805-7. PubMed ID: 22519914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.
    Kesselheim AS; Treasure CL; Joffe S
    PLoS Med; 2017 Jan; 14(1):e1002190. PubMed ID: 28045970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care policy. Reforming off-label promotion to enhance orphan disease treatment.
    Liang BA; Mackey T
    Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234
    [No Abstract]   [Full Text] [Related]  

  • 7. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
    Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
    Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The European Union Policy in the Field of Rare Diseases.
    Moliner AM; Waligora J
    Adv Exp Med Biol; 2017; 1031():561-587. PubMed ID: 29214592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model of effective health policy: the 1983 Orphan Drug Act.
    Reaves ND
    J Health Soc Policy; 2003; 17(4):61-71. PubMed ID: 17824591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexit and rare diseases: big risk, bigger opportunity?
    Hyry HI; Cox TM; Roos JC
    Curr Med Res Opin; 2017 Apr; 33(4):783-784. PubMed ID: 28100081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act.
    Thamer M; Brennan N; Semansky R
    J Health Polit Policy Law; 1998 Apr; 23(2):265-90. PubMed ID: 9565894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in orphan drug development and regulatory policy in China.
    Cheng A; Xie Z
    Orphanet J Rare Dis; 2017 Jan; 12(1):13. PubMed ID: 28100254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Med Sci (Paris); 2016 Apr; 32 Spec No 1():34-9. PubMed ID: 27137860
    [No Abstract]   [Full Text] [Related]  

  • 18. Legal and regulatory aspects of orphan drugs.
    Shani S; Yahalom Z
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():110-5. PubMed ID: 24380129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
    Herder M
    Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
    Karas L; Lu CY; Agrawal PB; Asgari MM
    J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.